Clinical Utility of Biochemical Markers of Bone Remodeling
نویسندگان
چکیده
منابع مشابه
[The clinical utility of biochemical markers of bone remodeling].
Remodeling is essential for bone health. It begins with resorption of old bone by osteoclasts, followed by the formation of new bone by osteoblasts. Remodeling is coupled (formation is linked to resorption). After middle age or perhaps beginning earlier, bone loss occurs because resorption exceeds formation. This imbalance is accentuated by estrogen deficiency as well as by many diseases and co...
متن کاملClinical Value of the Biochemical Markers of Bone Remodeling in the Assessment of Bone Metabolic Diseases
In clinical practice, low bone mineral densi ty (BMD) and, therefore, scarcity of bone mineral is identified and quantified by dual energy X-ray absorptio-metry (DXA) (1). However, BMD predicts only 66Ê74% of variance of the bone strength (2), and many individuals with normal areal BMD suffer fractures (3). It is well recognized that other aspects of bone composition and structure may contribut...
متن کاملBiochemical markers of bone turnover and their utility in osteoporosis.
O steoporosis, an age-related, degenerative disease of bone is an asymptomatic disease that is diagnosed after an already unacceptable loss of bone has occurred. Alternatively, a compression fracture may lead to the initial diagnosis. Diagnosis is established by bone mineral density (BMD) at the hip and/or spine.1 BMD is a static measure of bone composition, reflecting its “history,” and detect...
متن کاملClinical application of biochemical markers of bone turnover.
With the ageing population in most countries, disorders of bone and mineral metabolism are becoming increasingly relevant to every day clinical practice. Consequently, the interest in, and the need for effective measures to be used in the screening, diagnosis and follow-up of such pathologies have markedly grown. Together with clinical and imaging techniques, biochemical tests play an important...
متن کاملAdditive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women with osteoporosis. This phase 3, randomized, double-blind 1-yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less tha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Chemistry
سال: 1999
ISSN: 0009-9147,1530-8561
DOI: 10.1093/clinchem/45.8.1359